Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment.
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2015
At a glance
- Drugs Letrozole (Primary) ; Tamoxifen (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 04 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 11 Aug 2009 New trial record